Show source-provided references
9. Pathogenesis of lysosomal storage disorders as illustrated by Gaucher disease
10.1007/BF00710267 ↗11. Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders
10.1007/s13346-012-0072-4 ↗16. Current treatment options and novel nanotechnology-driven enzyme replacement strategies for lysosomal storage disorders
10.1016/j.addr.2022.114464 ↗19. Polymer-based drug delivery systems under investigation for enzyme replacement and other therapies of lysosomal storage disorders
10.1016/j.addr.2022.114683 ↗25. Suggested Procedures for the Reproducible Synthesis of Poly(d,l-lactide-co-glycolide) Nanoparticles Using the Emulsification Solvent Diffusion Platform
10.2174/1573413714666180313130235 ↗30. Biodegradable PLGA Nanoparticles Restore Lysosomal Acidity and Protect Neural PC-12 Cells against Mitochondrial Toxicity
10.1021/acs.iecr.9b02003 ↗31. Intertwined mechanisms define transport of anti-ICAM nanocarriers across the endothelium and brain delivery of a therapeutic enzyme
10.1016/j.jconrel.2020.05.009 ↗32. Muntimadugu, E., Silva-Abreu, M., Vives, G., Loeck, M., Pham, V., Del Moral, M., Solomon, M., and Muro, S. (2022). Comparison between Nanoparticle Encapsulation and Surface Loading for Lysosomal Enzyme Replacement Therapy. Int. J. Mol. Sci., 23.
10.3390/ijms23074034 ↗34. Enhanced Delivery and Effects of Acid Sphingomyelinase by ICAM-1-Targeted Nanocarriers in Type B Niemann-Pick Disease Mice
10.1016/j.ymthe.2017.05.014 ↗36. Brain-targeted enzyme-loaded nanoparticles: A breach through the blood-brain barrier for enzyme replacement therapy in Krabbe disease
10.1126/sciadv.aax7462 ↗38. Salvalaio, M., Rigon, L., Belletti, D., D’Avanzo, F., Pederzoli, F., Ruozi, B., Marin, O., Vandelli, M.A., Forni, F., and Scarpa, M. (2016). Targeted polymeric nanoparticles for brain delivery of high molecular weight molecules in lysosomal storage disorders. PLoS ONE, 11.
10.1371/journal.pone.0156452 ↗39. Rigon, L., Salvalaio, M., Pederzoli, F., Legnini, E., Duskey, J.T., D’Avanzo, F., De Filippis, C., Ruozi, B., Marin, O., and Vandelli, M.A. (2019). Targeting brain disease in MPSII: Preclinical evaluation of IDS-loaded PLGA nanoparticles. Int. J. Mol. Sci., 20.
10.3390/ijms20082014 ↗40. Brain-targeted polymeric nanoparticles: In vivo evidence of different routes of administration in rodents
10.2217/nnm.12.172 ↗41. Use of Polylactide-Co-Glycolide-Nanoparticles for Lysosomal Delivery of a Therapeutic Enzyme in Glycogenosis Type II Fibroblasts
10.1166/jnn.2015.9251 ↗42. Drug Release Kinetics and Transport Mechanisms of Non-degradable and Degradable Polymeric Delivery Systems
10.1517/17425241003602259 ↗46. A novel approach to monitor intracellular degradation kinetics of poly(lactide-co-glycolide) nanoparticles by means of flow cytometry
10.1039/C3TB21330G ↗47. Polymer degradation and drug delivery in PLGA-based drug-polymer applications: A review of experiments and theories
10.1002/jbm.b.33648 ↗49. A complete deficiency of Hyaluronoglucosaminidase 1(HYAL1) presenting as familial juvenile idiopathic arthritis
10.1007/s10545-011-9343-3 ↗50. Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX
10.1073/pnas.96.11.6296 ↗52. Zeta Potential and Colloidal Stability Predictions for Inorganic Nanoparticle Dispersions: Effects of Experimental Conditions and Electrokinetic Models on the Interpretation of Results
10.1021/acs.langmuir.1c02056 ↗54. A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1
10.1242/jcs.00367 ↗55. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers
10.1038/mt.2008.127 ↗56. Intercellular adhesion molecule 1 engagement modulates sphingomyelinase and ceramide, supporting uptake of drug carriers by the vascular endothelium
10.1161/ATVBAHA.111.244186 ↗57. Biological functionalization of drug delivery carriers to bypass size restrictions of receptor-mediated endocytosis independently from receptor targeting
10.1021/nn404719c ↗58. Caveolae: From basic trafficking mechanisms to targeting transcytosis for tissue-specific drug and gene delivery in vivo
10.1016/S0169-409X(01)00141-7 ↗60. Current developments and applications of microfluidic technology toward clinical translation of nanomedicines
10.1016/j.addr.2017.08.003 ↗61. Ultra-high throughput synthesis of nanoparticles with homogeneous size distribution using a coaxial turbulent jet mixer
10.1021/nn501371n ↗62. Characterization of degradation behavior for PLGA in various pH condition by simple liquid chromatography method
64. Formulation, characterization, and cellular toxicity assessment of tamoxifen-loaded silk fibroin nanoparticles in breast cancer
10.1080/10717544.2021.1958106 ↗66. Quantitative detection of PLGA nanoparticle degradation in tissues following intravenous administration
10.1021/mp300559v ↗69. Effects of acid exposure on the conformation, stability, and aggregation of monoclonal antibodies
10.1002/prot.21243 ↗72. Benita, S. (2006). Microencapsulation Methods and Industrial Applications, Taylor & Francis.
73. A method to improve quantitative radiotracing-based analysis of the in vivo biodistribution of drug carriers
10.1002/btm2.10208 ↗74. Protein instability toward organic solvent/water emulsification: Implications for protein microencapsulation into microspheres. P.D.A